Grifols, a Spanish multinational specializing in plasma-derived therapies, is undervalued due to historical mismanagement but holds a strong market position with significant competitive advantages ...

(Bloomberg) -- Four investment groups with ties to the family that owns about 35% of Grifols SA confirmed they are in talks with Brookfield Asset Management Ltd. over a potential offer for the ...

An injection of anti-Rh antibodies (widely known by the trade name RhoGAM) given to the mother soon after birth neutralizes any fetal blood cells in their circulation before their immune system ...

In its first-quarter 2025 investor letter, White Falcon Capital Management highlighted stocks such as Grifols, S.A. (NASDAQ:GRFS). Grifols, S.A. (NASDAQ:GRFS) is a plasma therapeutic company.

Grifols stock price traded 12% higher to €9.10 on Wednesday on the Spanish stock exchange. More on Grifols S.A. Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale ...

Spanish pharma company Grifols' shares up on Brookfield talk Shares in Spanish pharmaceutical company Grifols rose on Wednesday after Canadian fund Brookfield said it was talking with shareholders ...

Grifols and IBL, a Tecan company, seek to revolutionize clinical diagnostics with a future high-sensitivity, multiplexed immunoassay platform MÄNNEDORF, Switzerland, April 08, 2025--(BUSINESS ...

In its first-quarter 2025 investor letter, White Falcon Capital Management highlighted stocks such as Grifols, S.A. (NASDAQ:GRFS). Grifols, S.A. (NASDAQ:GRFS) is a plasma therapeutic company. The ...